Business Context and Reporting Period
This Form 8-K filing by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) reports on the results of the 2018 Annual Meeting of Stockholders held on May 18, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes
No material financial changes are reported. The filing details the outcome of two shareholder proposals:
- Proposal 1: Election of two directors (Daniel M. Junius and Rachel K. King) to serve until the 2021 annual meeting. Both nominees were elected.
- Proposal 2: Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. The appointment was ratified.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, or discussion of contingencies. It strictly reports the voting results of the annual meeting.
Important Facts for Investors
- Shareholder Participation: 92.9% of outstanding shares (39,460,245 of 42,491,487) were present or represented by proxy.
- Director Election Results: Daniel M. Junius received 31,810,245 votes for (2,130,469 withheld). Rachel K. King received 31,845,824 votes for (2,094,890 withheld). There were 5,519,531 broker non-votes.
- Auditor Ratification: Ernst & Young LLP received 39,377,293 votes for, with 42,976 against and 39,976 abstentions.
- Company Name Discrepancy: The input metadata referenced "Crescent Biopharma, Inc.," but the filing text explicitly identifies the registrant as "GlycoMimetics, Inc."